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CANCER COMMITTEE CHAIRMAN’S FOREWORD

sity. By dealing with the full range of oncology
diagnoses, the oncology program remains com
mitted to the understanding and treating of all
problems associated with patients with cancer.
During the past year, the committee has strived
to improve the overall aspects of oncology care
and delivery for the patients at West Allis
Memorial Hospital. To help with this plan, two
clinical indicators sponsored by the Joint
Commission on the Accreditation of Hospitals
Organization were implemented in the past
year. These indicators test the appropriateness
and availability of information within the
medical record to insure that patients have an
adequate amount of information so that
appropriate decisions can be made. While
these indicators may be mandatory in the
future, at this point in time, it is only through
an organizations own initiative that they are
performed. We are happy with the results of
these indicators though continued work to
insure this excellent response needs to be
maintained.

Kevin J. Murray, M.D., Chairman
The Cancer Committee is a multidisciplinary
committee whose function is the overseeing
and monitoring of all of the oncology aspects at
West Allis Memorial Hospital. In addition to
supervising educational efforts for the medical
staff, nursing and the general public, the
committee supervises the submission of data to
the American College of Surgeons who directs
both short-term and long-term patient care
evaluations.

The Cancer Committee also supervised our
participation in both short-term and long-term
patient care evaluation studies of patients with
cancers of the esophagus. This participation
forms a basis for our report this year and later
in this booklet, you will find articles describing
the surgery, chemotherapy and radiation
therapy aspects of these types of cancers.
Throughout this year, as well as the years in
the past, the cancer program at West Allis
Memorial Hospital has maintained its tradition
of excellence in the therapy and the support of
those patients afflicted with this disease. All of
these efforts require the continued dedication
of all those who participate and I applaud their
continued excellent work.

This year remained a very active time for all the
members of the oncology program. Over 975
cases were diagnosed or treated at West Allis
Memorial Hospital. While cancers of the female
breast, prostate, lung and colon represented
approximately 50% of all of the patients seen,
a major strength of the oncology program at
West Allis Memorial Hospital remains its diver-
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INTRODUCTION

West Allis Memorial Hospital offers a compre
hensive program for the detection, prevention,
and treatment of cancer, and rehabilitation of
the patient. Our Cancer Program has many
facets, each contributing to our mission of
caring for and improving the lives of people
stricken with cancer.

Cancer is more than a physical disease. It
often undermines the psyche, the family, and
economic security. An important part of our
mission is to deal with these factors with the
same intense dedication brought to the physical
well-being of each patient.
Cancer support services encompasses a network of services and personnel whose mission
is to enable people with cancer who are currently undergoing treatment and those who are
not, those who are living with disease and
those who survived it, their families and their
friends, to cope with the stress and changes in
their lives that cancer and its treatment can
render.

Once cancer has been diagnosed, a treatment
plan is developed to meet the special needs of
the individual.
Our multidisciplinary team of highly skilled
physicians and healthcare professionals provide
state-of-the-art specialized medical care, aided
by the latest technology. Cancer treatment is
constantly evolving, taking advantage of new
discoveries and technology.

This report contains a description of the activ
ties within the Cancer Program in 1 995 and
illustrates the patient volume in each tumor
site. In addition, attention is focused on our
indepth study of esophageal cancer, including
articles by physicians who diagnose and treat
esophageal cancer.

Rehabilitation is an important component of
cancer care whether the patient is receiving
therapy for cure or palliation. The general goal
of rehabilitation is to reach the fullest potential
of the individual within his or her environment,
with due consideration of the cancer site,
histology, stage, treatment and the patient’s
age and condition.

11

7995 CANCER COMMITTEE MEMBERS

MEMBER

SERVICE

Kevin J. Murray, M.D., Chairman

Radiation Oncology

Linda J. Barrows, M.D.

Physical Medicine

Donald Blatnik, M.D.

Otolaryngology

Donald L. Feinsilver, M.D.

Psychiatry

David Foley, M.D.

Gynecology/Oncology

Richard E. Fuller, M.D.

Family Practice

Jeffrey B. Gorelick, M.D.

Physical Medicine

John F. Pope, M.D.

Urology

Terence V. Roth, M.D., ACoS Liaison Physician

General Surgery

Steven D. Sperling, M.D.

Diagnostic Radiology

Robert Taylor, M.D.

Hematology/Oncology

Shelly Underhill, M.D.

Pathology

Mark D. Wilcox, M.D.

Anesthesiology

J. Frank Wilson, M.D.

Radiation Oncology

Richard Kellar

Vice President

Beverly Hochtritt, R.N.

Nursing Administration

Barbara Daso, R.R.A.

Director of Health Information Services

Vicki Shackley, R.N.

Director of Quality Assessment

Carmen Bolger-Linna, R.N., O.C.N.

Oncology Nursing

Priscilla Eckert, A.R.T., C.T.R.

Cancer Registrar

111

TABLE OF CONTENTS

Tumor Board Report

1

Cancer Registry Report

2

Cancer Program Services

4

Breast and Cervical Cancer Screening Program

6

Accession Year Distribution

8

Primary Site Tabulations for 1 995

9

Cancer of the Esophagus

13

Pathology of Esophageal Cancer

13

Esophageal Cancer Diagnosis and Therapy

15

Current Issues in Esophageal Cancer Surgery

18

Radiation Therapy for Carcinoma of the Esophagus

21

Current Role of Chemotherapy for Esophageal Carcinoma

23

Patient Care Evaluation Study Results of Carcinoma of the Esophagus

26

Glossary

31

iv

TABLE OF CONTENTS

Tumor Board Report

1

Cancer Registry Report

2

Cancer Program Services

4

Breast and Cervical Cancer Screening Program

6

Accession Year Distribution

8

Primary Site Tabulations for 1 995

9

Cancer of the Esophagus

13

Pathology of Esophageal Cancer

13

Esophageal Cancer Diagnosis and Therapy

15

Current Issues in Esophageal Cancer Surgery

18

Radiation Therapy for Carcinoma of the Esophagus

21

Current Role of Chemotherapy for Esophageal Carcinoma

23

Patient Care Evaluation Study Results of Carcinoma of the Esophagus

26

Glossary

31

iv

TUMOR BOARD
cancer treatment which offer the best chance
of response and survival.

Virtually all patients with cancer are diagnosed
in the primary care setting and the majority (78
to 80 percent) receive all their care in commun
ity hospitals The initial evaluation and treatment decisions are the most critical in the outcome of the patient with cancer; but cancer is
a systemic illness that can rarely be detected,
diagnosed, and adequately treated by one
physician.

Equally important is the educational aspect of
the Tumor Board. The non-cancer specialist in
attendance is informed in areas of prevention,
early diagnosis, and treatment. Attendees have
the opportunity to ask questions or have points
of information clarified. Allied health profes
sionals attending the conferences also enjoy
Indirectly these
these educational benefits
physicians and
the
because
benefit the patient
treat cancer
who
professionals
allied health
result of the
a
as
informed
patients are better
of care
quality
overall
The
conferences.
improved.
thereby
is
hospital
delivered by the

The Tumor Board of West Allis Memorial is a
multidisciplinary cancer conference which is
held weekly. These conferences focus on the
diagnosis, pretreatment evaluation, staging,
treatment strategy, and rehabilitation of cancer
patients. Cases with special educational value
or unusual clinical findings or patients with
multiple medical problems which complicate
treatment decisions are often discussed at
conference.

.

Tumor Board provides a mechanism for review
of professional practices within the hospital for
the purpose of reducing morbidity and mortality
through outcome analysis.

The primary goal of the Tumor Board is to
improve the care of cancer patients through the
exchange of information among the partici
pating physicians. Local specialists share their
expertise which is based on their experience, as
well as a knowledge of the current literature.
In this environment the primary care physician
can take advantage of the expertise of his
colleagues and be informed of the current
clinical trials that may benefit his/her patient.

In 1 995, an average of 3 patients per week
were presented at Tumor Boards. The average
weekly attendance was 32.
The Tumor Boards are held every Friday and
Continuing Medical Education programs are
held on Tuesdays. Sessions are held in meeting
rooms A and B at noon, on their respective
days. The programs are approved for continu
ing education credits by the Wisconsin Medical
Association, and the American Academy of
Family Practice for one credit hour in Category
I of the Physicians’ Recognition Award of the
American Medical Association.

Through participation at the Tumor Board the
family physician is confident that he/she can
offer not only comprehensive and empathetic
care, but also the most up-to-date advances in

CANCER-RELA TED CONTINUING MEDICAL EDUCA TION PROGRAMS
Date

Subject

Speaker

5/23/95

What’s New in Urologic Oncology

Mark Rosen, M.D.

9/1 2/95

Screening for Bethesda System
Cervical Cancer

David Ferguson, M.D.

11/14/95

Psychological Factors of Breast
Cancer Reconstruction

Rebecca Anderson, M.D.

11/28/95

Office Proctology

David Heber, M.D.
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CANCER REGISTRY
Data System

Confidentiality Maintained

West Allis Memorial Hospital Cancer Registry is
a comprehensive data system for the collection,
management and analysis of data on persons
with cancer. The registry is patterned to meet
the requirements of the American College of
Surgeons, Commission on Cancer.

Confidentiality regulations are always observed
in the release of information. Only aggregate
data is submitted for national studies. Confi
dentiality of patients and physicians is strictly
maintained. Seventeen requests for data was
received by the registry in 1 995 from staff
physicians and hospital staff.

Main Objective
Data Quality Measures
The Cancer Registry is designed to describe
trends in patient and disease characteristics,
modalities of therapy and patient survival
experiences. The main objective of the registry
is to make basic knowledge about West Allis
Memorial’s experience available to the members
of the medical staff in order to evaluate the
results of patient care. It is hoped that this
information will further improve the diagnosis
and management of cancer patients. Registry
incidence data also aids in administrative
planning and for use in program planning.

Accuracy of the data is extremely important
and several measures are in place to insure
quality data. The Cancer Committee reviews
1 0% of the cases accessioned each year. This
is accomplished by physician review comparing
the abstracts with the information in the
medical record.
Studies are reviewed for
accuracy prior to submission by a physician
member of the Cancer Committee. Abstracts
are routinely edited for completeness, logic and
consistency. This is accomplished by editing of
printed computer reports, automatic computer
edits, and by running error reports provided in
the registry software program.

Computerized Data
The data collected is entered on to a computer
software program of Electronic Registry
Systems. Computerized data enables prompt
retrieval of information, automated printing of
follow-up letters, and a paperless registry.

Follow-up Activities
Cancer patients are followed by the registry for
the lifetime of the patients. Patient follow-up
is a necessary function of the registry and at
least a 90% follow-up rate is necessary in order
to have meaningful survival data. In 1995 the
follow-up rate average was 94%, surpassing
the 90 percent requirement of the American
College of Surgeons.

Registry Start Date
The registry has cancer data from January 1,
1978 (the official start date of the Cancer
Program at West Allis Memorial) and has
accessioned over 1 3,000 new cancer cases.

Patient follow-up also serves as an automatic
reminder to the physician to schedule regular
physical examinations, and provides outcome
data for comparison with regional and national
norms.

Reporting Activities
Cancer data reporting to the Wisconsin State
Department of Health, Cancer Reporting
System, has been required by legislation as of
January 1 1 978. The registry is responsible for
this function. In 1995 the Cancer Committee
agreed to participate with other hospitals in the
United States by providing requested cancer
data to the National Cancer Data Base (NCDB).

Staff to Cancer Committee

,

The registry works closely with the Cancer
Committee. Under the auspices of the Cancer
Committee, the registry assures that all
components for an approved Cancer Program
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Society, the
Association, the American Cancer
anagement
American Health Information
Infor
Association and the Wisconsin Health
Active
matiOn Management Association
effort to
membershiPs are maintained in an
future
and
keep abreast of all the current
as
field
information
changes in the health care
also
meetings
it relates to cancer. Association
information on
provide training and invaluable
collection
changes in the cancer registry data
in
changes
requirements as well as current
cancer diagnosis and treatment.

The registry assisted the
are maintained.
summarizing data
committee by collecting and
Surgeons tong and
for the American College of
patient care
short-term esophageal cancer
studies can
evaluation studies (results of these
of this report).
be found in another part
data was also
Collection and summarization of
Indicator
accomplished for the two Clinical
registry assisted the
studies. In addition, the
the American
committee in the participation of
Cancer
College of Surgeons and American
information
Society Patient Survey Study. The
study should
gathered by participation in this
meet the needs of
help us better identify and
families. The
the cancer patients and their
the Cancer
registry also serves as staff to
Tumor Boards,
Committee, takes minutes of
of the Cancer
and assists in the preparation
Program Annual Report.

.

Inquiries Welcomed
inquiries and the
The registry staff welcomes
members to
opportunity to assist medical staff
be made by
can
retrieve cancer data. Requests
calling 328-7122.
Priscilla Eckert, ART, CTR
Cancer Registrar

Continuing Education
are active
The Cancer Registry staff
Registrars’
participants in the Wisconsin Cancer
Registrars’
Association, the National Cancer

Sharon Miller
Follow-up Service
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CANCER PROGRAM
From the moment of ent
ry into West Allis
Memorial Hospital each pat
ient and their family
is guided through the can
cer care system with
the conscientious suppor
t of medical experts
who understand the men
tal and physical tolls
of the disease and treatm
ent processes.
Oncology Inpatient Uni
t
The oncology unit is a
dedicated 30 bed unit
located on 6 North. Thi
s clustering assures
expert staffing. An entire
team of health care
professionals, including
physicians, nurses,
therapists, dietitians, and
pharmacists are
involved in the one-on-on
e individual care of
the cancer patient. The
enterostomal therapist
provides a very importan
t role in the rehabil
itation of cancer patients
who undergo ostomy
surgery. Mastectomy tea
ching is provided by
the oncology nursing sta
ff for breast cancer
patients following surger
y. Keeping up with
new technology, chemo
therapy protocols or
nursing innovations is ma
naged by the Oncol
ogy Nursing Committe
e.

SERVICES

enables attainment of
patient treatment goals.
Board-certified physia
trists are available for
consultation.
Community Education
Health improvement
educational programs
designed to serve our
patients, their families
and everyone in the sur
rounding communities
are offered on a routine
basis. A dedicated
staff of health profes
sionals deal in group
instructions for det
ection, prevention and
promotion of a healthy
lifestyle. Some of the
cancer-related programs
offered in 1 995 were:
,

Wise Food Choices for
a Healthy GI Tract
by Kathy Haas, R.D., M.S
.

. Making Healthy Cho
ices at the Supermarke
t
by Mary B. Hartwig, R.N
., M.S., R.D.
. Dispelling Myths abo
ut Pap Smears
by Mary Reznicek, M.D.
Community Services

Outpatient Oncology Uni
t
The outpatient oncology
unit can accommodate
up to 40 patients. Medica
l oncologists see and
treat their patients in
the outpatient clinic.
Chemotherapy is a freque
ntly used modality for
the treatment of cancer
. Although some regi
mens of chemotherapy
require hospitalization,
the majority can be adm
inistered on an outpatient basis.
Radiation Oncology De
partment

When the cancer patien
t leaves the direct care
of the hospital a netwo
rk of support and caring
is extended out into the
community. The chal
lenge is to ensure con
tinuity of care as the
patient moves out to the
home or institutional
settings in the communit
y. Following are but a
few examples of thi
s network which is
extended not just to the
cancer patient and
their families, but to
all patients and the
community as a whole.
. Home Care
West Allis Memorial has
teamed up with variou
s other agencies to
provide home care for
community residents.
This combination of exp
ertise and resources
can supply community
residents with everything they need from
nursing to nutrition to
equipment.

The radiation oncolo
gists at West Allis
Memorial Hospital can offe
r the cancer patient
external beam radiation
delivered by linear
accelerator plus i nterstiti
al and intracavity
brachytherapy, and the
opportunity to parti
cipate in national treatm
ent protocols.

-

Rehabilitation Services

. Meals Ala Wheels
This hospital program
consists of the delivery of
nourishing appetizing
meals, by volunteers,
to community residents
who wish to remain at
home, but are unable to
cook for themselves. Thi
s program has been in
existence since 1 967.
-

Rehabilitation Services
provides inpatient and
outpatient physical the
rapy, occupational
therapy and speech pat
hology services to the
cancer patient. The coo
rdinated team approach
4

American Cancer Society. The program is
designed to help patients and their loved ones
understand the day-to-day issues of living with
a chronic disease like cancer.

The
WAMH Van Patient Transportation
to
available
is
WAMH Van courtesy shuttle
any
for
hospital
the
drive patients to and from
outpatient test and service or hospitalization.
This service is free and is available weekdays
for patients able to walk unassisted or with
walking aids.
,

-

If patients
. Home Laboratory Services
but have
drawn
samples
need to have blood
staff
laboratory
hospital
the
difficulty coming to
the
collect
to
home
patients
will come to the
samples.

Informational
.
Living Through Loss”
series that provides an opportunity to learn
about loss and grief. The stages of grief, the
accompanying life changes and ways to move
beyond loss are discussed. This provides a
healing environment for people to share their
own personal stories and ways of coping with
grief.

The
. Mammography Screening Center
cancer
breast
cost
low
offers
Screening Center
screening and self-examination education in a
pleasant environment.

This group
.
“Care for the Caregiver”
provides a supportive atmosphere for caregivers
to discuss concerns, vent frustrations and
share ideas for coping.

Annual
“Great American Smokeout”
to quit
persons
encourage
to
hospital event
smoking.

. National Cancer Survivors Day This is a
“Celebration of Life” co-sponsored by West
Allis Memorial, St. Luke’s Medical Center and,
The American Cancer Society annually for
cancer survivors, their families, caregivers and
The celebration is an
the community.
opportunity to share the joy of victory over
cancer.
Research

“

-

-

-

,

-

-

-

Support Services
Several support groups are offered for persons
with cancer, their families and friends. In
addition to the support groups spiritual support
is offered for the patients through chaplin
The support groups provide an
services.
opportunity to share concerns and ideas for
coping with illness and to help people live
within the limits of the disease process.

Participation in national study groups assures
patients of the newest treatments available
including research protocols. The Institutional
Review Board (IRB) is responsible for the
review and approval of all protocols with
Patients have been
patient participation.
enrolled in research protocols through the:

. “Positive People” New insights and information can be gained through sharing common
experiences with others whose lives cancer has
touched. One of the goals of this support group
is to help people recognize that individuals who
have cancer can continue to lead productive,
meaningful lives.
-

. Radiation Therapy Oncology Group (RTOG)
. National Surgical Adjuvant Breast/Bowel
Project (NSABP)
. Cancer Control Research including:
Cancer Screening Programs
Identification of high risk groups
Nutritional Counseling

This is a nationally
.
“I Can Cope”
program offered
education
recognized patient
of the
cooperation
the
with
at the hospital
-
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BREA ST CANCER AND CERVICAL CANCER SCREENING
PROGRAM
By Nancy Rhodes, R.N.
ment, transportation and access to the
health care system;
3. To recruit providers throughout
suburban Milwaukee Countyto increase
access and provide a close, convenient
screening site;
4. To assist health departments in
reaching eligible women within their
specific communities;
5. To maintain a coalition of community
representatives;
6. To network and coordinate with
health and community organizations to
prevent duplication, identify women
who qualify for free screening and
promote outreach activities.

I

As coordinator of the project, it is my responsi
bility to oversee this multi-community effort. I
am employed by and housed at West Allis
Memorial Hospital who has been an active participant through the Mammography Screening
Center and Radiology.

Nancy Rhodes, R.N.
The Wisconsin Women’s Cancer Control Prog
ram (WWCCP), Suburban Milwaukee County, is
a public-private partnership between the 1 2
suburban health departments and West Allis
Memorial Hospital.
The West Allis Health
Department is the fiscal agent for the project,
which began in May of 1 994. Funding is from
the State of Wisconsin who successfully
competed for a five-year grant from the U.S.
Centers for Disease Control and Prevention to
substantially reduce the deaths due to breast
cancer. There is a WWCCP program in each
county in Wisconsin and all states are partici
pating.

Women are qualified to receive a screening
and/or diagnostic mammogram, fine needle
aspiration superficial and fine needle aspiration,
deep tissue under radiology guidance paid by
the program at Medicare rates, if they are 50
years of age and older and meet the income
guidelines which are based on 200% of pover
ty. Currently one individual can have a gross
household income of $1 5,480, or two persons
$20,720. Many women in the 50-65 year age
group may be working at jobs providing no
health insurance or have a high deductible.
Many Medicare eligible women live on Social
Security and are eligible during the off year in
which Medicare does not cover the cost of
their mammogram.

The goals of the project are:
1 To increase the number of women
50 and over who are screened with
special emphasis on those who are
under/uninsured, low income (200% of
poverty), and have a high deductible if
they have insurance;
.

Screening began in October, 1 994 and through
the first fiscal year of 1 0/01 /94 through
09/30/95, West Allis Memorial screened 85
women of the total 1 07 under this program. In

2. To eliminate barriers such as pay6

We know there are 58,000 women 50 years of
age and older in Suburban Milwaukee County
with an unknown number who may qualify.
One of the largest challenges has been iden
tifying those women. Each community has and
is involved in recruitment and education efforts
in reaching women. Mobile mammography has
been a successful effort at low income housing
units, community centers, and long term care
facilities who invite their community neighbors.
West Allis Memorial’s Admitting and Mammo
graphy Center have been especially alert to
patients who may qualify. Our goal is to screen
500 women in the next fiscal year, 10/01/96
through 09/30/97.

the past fiscal year, 10/01/95 through
09/30/96, 86 of the estimated 200+ women
screened were at West Allis Memorial Hospital.
Other providers who participate are St. Luke’s,
St. Luke’s South Shore, St. Mary’s, St.
Joseph’s, Sinai-Samaritan, Aurora Medical
Group West, and Mobile Diagnostic testin’g
through Aurora. In Suburban Milwaukee Coun
ty, two breast cancers were detected and
treated. Within the State of Wisconsin, 7,000
women were screened from June 1 1 994,
through August 30, 1996, and 14 breast
cancer were detected and treated.
,

The other component for the program is provision of Pap tests, screening and diagnostic,
colposcopy without biopsy and with directed
biopsy. Several physicians and Planned Parenthood are the providers of these services. In the
cervical area, JO were CIN I, 5 CIN Il-Ill, and
one invasive cancer were detected and treated.

If you have patients who may benefit from this
program, please have them call me, Nancy
Rhodes at 328-7407, or their local health
departments. For questions about the program
please contact Nancy Rhodes.
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WEST ALLIS MEMORIAL HOSPITAL
PRIMARY SITE TABULATION FOR 1 995 ACCESSIONS

PRIMARY SITE

TOTAL

CLASS
A

MALE GENITAL
PROSTATE

SEX
N/A

STAGE

N

F

0

I

II
81

17

25

22

79

17

25

21
0

III

IV

175

755

20

175

0

5

167

147

20

167

0

4

25
21

TESTIS

6

6

0

6

4

2

0

2

2

0

2

0
0

0

OTHER

1

0

0

0

0
0

URINARY SYSTEM

UNK

1

74

61

13

46

28

26

JO

11

4

10

13

BLADDER

53

42

11

35

18

26

10

5

1

7

10

KIDNEY/RENAL
OTHER

18

17

1

10

8

0

0

6

3

7

2

3

2

1

1

2

0

0

0

0

2

1

BRAIN&CNS

11

10

1

6

5

0

0

7

4

10

9

1

5

5

0

0
0

0

BRAIN

0

7

3

OTHER

1

1

0

1

0

0

0

0

0
0

0

1

ENDOCRI NE

11

11

0

0

5

4

1

0

1

11

11

0

5
5

6

THYROID

6

0

5

4

1

0

1

0

0

0

0

0

0

0

0

0

0

0

37

33

4

14

23

0

4

10

6

11

6

5

4

1

1

0

0

2

2

1

0

NON-HODGKIN’S

32

29

3

13

4
19

0

4

8

4

JO

6

UNKNOWN PRIMARY

21

21

0

8

13

0

0

0

0

0

21

3

2

1

2

1

0

0

0

0

0

3

OTHER

LYMPHATIC SYSTEM
HODGKIN’S DISEASE

OTHER/ILL-DEFINED

Number of cases exctuded: 0
This report INCLUDES CA in-situ cervix cases, and squamous and basal ceLl skin cases.

KEY
CLASS A

ANALYTIC CASE
THIS HOSPITAL

CLASS N/A

NONANALYTIC CASE
PATIENTS DIAGNOSED AND TREATED ELSEWHERE WHO WERE SEEN
HOSPITAL FOR RECURRENCE OR PERSISTENT DISEASE OR WERE FIRST DIAGNOSED
AT AUTOPSY

STAGE 0

IN SITU STAGE

STAGE BEN

BENIGN TUMORS

STAGE UNK

UNKNOWN STAGE
STAGING WORKUP WAS NOT COMPLETED OR THERE IS NO STAGING SCHEME FOR THE
SITE (SUCH AS HEMATOPOIETIC PRIMARY SITES)

-

PATIENTS DIAGNOSED AND/OR RECEIVED ALL OR PART OF THEIR FIRST COURSE OF THERAPY
AT

-

-

AT THIS

NONINVASIVE CANCER

-
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WAMH when compared with the rate for the
United States.

The distribution tables (shown on the opposite
page) display the most frequent sites by sex
comparing West Allis Memorial Hospital with
the incidence in the United States.

The rank of the sites for female cancers by
incidence differs between WAMH and the
United States, but only by one to three
percentage points. Lung cancer ranks second
in the nation for females and third at WAMH.
Lung cancer ranks as number one site as the
cause of death from cancer for both sexes,
both at WAMH and in the nation.

The site with the largest number of new cases
was the female breast with 1 79 cases acces
sioned. Only one male breast cancer was
diagnosed in 1995. The primary sites that
accounted for approximately half of all female
cancer cases were breast (35%) and colon and
rectum (11%).

The stage at diagnosis table (shown below)
compares the most frequent sites of cancer of
WAMH and the SEER program. WAMH cases
compare favorably with the SEER cases by
stage at the time of diagnosis. WAMH has a
higher percentage of localized stage cases than
SEER for lung, female breast, cervix uteri,
ovary, prostate and bladder. A lower percentage of patients diagnosed with distant
disease was evident at WAMH for all sites
except the corpus uteri. The percentage of
distant stage disease for colon and rectum was
tied at 19%.

Prostate cancer was the second most frequent
site with 1 67 cases accessioned and was the
most frequent site among males. Half of the all
male cancer patients had primary tumors of the
prostate (36%) and lung (15%).
The rank of the sites for male cancers by
incidence is the same for WAMH and United
States. Although, at WAMH there is a three
percent higher incidence of colon and rectal
cancer and a two percent higher incidence of
urinary cancer than for the United States. There
is only a one percent increase in lung cancer at

PERCENT OF CANCER CASES BY STAGE AT DIAGNOSIS
SEER CASES 1983

WAMH 1995 CASES*

-

J990**

available to assign a stage to all cancer cases.
Note: Sites do not total 1 00 percent because sufficient data is not
*
* *

West Allis Memorial Hospital 1 995 Cancer Cases
Institute Cancer Cases
Surveillance Epidemiology and End Results Program of the National Cancer
1990
983
1
of
data
SEER
on
Source: American Cancer Society, based
-
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1995 DISTRIBUTION OF CANCER CAS
ES
PERCENTAGE OF SITES BY SEX

MALE
WAMH

SITE

UNITED STATES*

36%

PROSTATE

36%

15%

LUNG

14%

13%

COLON&RECTUM

10%

10%

URINARY

8%

5%

LEUKEMIA & LYMPHOMA

7%

2%

PANCREAS

2%

19%

ALLOTHERS

23%

FEMALE
ø

*

WAMH

SITE

UNITED STATES*

35%

BREAST

32%

11%

COLON&RECTUM

12%

10%

LUNG

13%

7%

CORPUS UTERI

8%

5%

URINARY

4%

5%

LEUKEMIA & LYMPHOMA

6%

3%

OVARY

5%

24%

ALL OTHERS

20%

Estimated 1 995 cancer cases from Ameri
can Cancer Society publication, Cancer
Statistics 1995
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PA THOL OG V OF ESOPHA GEAL CANCER
By Paul A. Angermeler, M.D.

tumor and nodal metastasis may be replaced by
necrotic tissue or hyalinized tissue with a giant
cell reaction. These presumptive findings of
tumor involvement are important to document
since prognosis may relate to the extent of
tumor involvement prior to chemotherapy
and/or radiotherapy.

The vast majority of malignant neoplasms of
Malignant
the esophagus are carcinomas.
stromal tumors (formerly called leiomyo
Squamous cell
sarcomas) are very rare.
carcinomas account for approximately 80%
85% of esophageal malignancies. Adenocar
cinomas constitute approximately 10% of
esophageal cancers, while rare forms of
carcinomas make up the rest.
-

Adenocarcinomas are most frequently located
in the middle and lower esophagus. Earlier
these were thought to arise in submucosal
glands in the esophageal wall. It is now recog
nized that the vast majority arise from a background of Barrett’s esophagus. This condition
refers to the replacement of normal squamous
epithelium by columnar epithelium. Chronic
gastroesophageal reflux causes inflammation
and ulceration of the squamous epithelial lining.
The healing process occurs by epithelialization
originating by pleuripotent stem cells. These
differentiate into metaplastic glandular epi
thelium in this acid environment.1 Barrett’s
metaplastic epithelium (defined by the presence
of goblet cells) is histologically identical to
intestinal metaplasia of the incomplete type in
the stomach. This histologic finding carries the
synonyms “distinctive’ “specialized” or Barrett’s metaplasia. Patients are at increased risk
for esophageal adenocarcinoma even when only
a short segment (1 cm or 2 cm) of esophagus
is involved by Barrett’s metaplastic epi
thelium 2
The pathologist’s role in evaluating patients
Barrett’s esophagus is
with suspected
threefold : (1 ) identify Barrett’s metaplastic

Squamous cell carcinoma is associated with
many risk factors, most notably excessive
alcohol consumption and tobacco use. Other
risk factors reported include lye strictures,
achalasia, human papilloma virus infection,
genetic factors, diet, Plummer-Vi nson
In the biopsy
syndrome and celiac sprue.
diagnosis of squamous cell carcinoma, the
pathologist may be challenged when tissue
taken at an ulcer may show severe basal cell
hyperplasia mimicking carcinoma in situ or
endothelial changes in granulation tissue may
Resection speci
resemble adenocarci noma
mens also present a substantial challenge to
the pathologist when intra-operative histologic
evaluation of the margins by frozen section is
Squamous cell carcinoma may
requested.
spread within the submucosa up to 5 cm or
more beyond the grossly visible tumor.
Multiple sections are required to include the
entire circumference as well as multiple levels
to identify submucosa and submucosal
lymphatics. Another practical problem includes
evaluation of resection specimens following
chemotherapy and radiotherapy. The primary
.

,

13

epithelium, (2) identify and grade glandular
dysplasia, and (3) detect intramucosal or
invasive adenocarcinoma, if present.

mucosa may be extensive or focal, thus
sampling needs to be thorough and systematic.
The dysplastic changes span a continuum from
minimal atypia to high grade dysplasia. A
generally accepted format includes the
categories: (a) negative for dysplasia, (b)
indefinite for dysplasia, (c) low grade dysplasia
and (d) high grade dysplasia.

The endoscopic diagnosis of
Barrett’s
esophagus may be problematic. The squamo
columnar mucosal junction does not always
coincide with the gastroesophageal junction.
Patients with large hiatal hernias may pose a
challenge to the endoscopist. Fortunately, if
the diagnosis of Barrett’s esophagus is based
on the histologic finding of metaplastic
epithelium, then the exact landmarks are not
critical. Moreover, the presence of metaplastic
epithelium anywhere within the gastroesopha
geal junction region is considered a predis
position for adenocarcinoma since adenocar
cinoma of the gastric cardia ia probably closely
related to adenocarcinoma in Barrett’s3

Frequently, regenerative and inflammatory
changes may closely resemble low grade
dysplasia, hence the category “indefinite for
dysplasia”. These patients may require followup biopsies after anti-reflux therapy for a more
definitive diagnosis.
Low grade dysplasia
results in increased surveillance. Patients with
high grade dysplasia may undergo an esophag
ectomy since esophageal resection specimens
resected for biopsy-proven high grade dysplasia
not infrequently demonstrate an unsuspected
invasive carcinoma.

The identification of glandular dysplasia within
the metaplastic epithelium of Barrett’s esopha
gus directly influences patient management. It
is hypothesized4 that adenocarcinoma arises in
Barrett’s esophagus through a sequence of
events beginning with chronic reflux and ending
with invasive tumor. This hypothesis identifies
the goblet cell (the diagnostic feature of
intestinal metaplasia) as an obligatory precusor
Dysplasia is
of dyplasia and then cancer.
recognized by the presence of architectural and
cytologic abnormalities in glandular epithelium
and classified as low or high grade. Sampling
error and imprecision in the histologic
evaluation of Barrett’s esophagus are problems
in the diagnosis of dysplasia. The dysplastic
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ESOPHA GEAL CANCER DIA GNOSIS AND THERAPY
By Franklin D. Loo, M.D.
In the rest of the world there are several ‘hot
zones” for squamous cell carcinoma of the
esophagus, for example, the “esophageal
cancer belt” that extends from northern China
to the Caspian Sea and the Transhei region of
South Africa. Both types of esophageal cancer
affect men more frequently than women.
Squamous cell cancer is three times more
common in men than in women, whereas
adenocarcinoma is approximately seven times
more common in men. Both are diagnosed
most often between the ages of fifty and
seventy.
Risk Factors
A. Squamous cell carcinoma.

.-/
/‘

.
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In the United States, cigarette smoking and
alcoholism are acknowledged risk factors.
Other potential risk factors include exposure to
carcinogens (nitrates) and thermal injury such
as drinking boiling hot tea.

/.

//j

Infection may also play a role in causing
squamous cell cancer of the esophagus. One
recent study found that twenty percent of
patients had evidence of human papilloma virus
infection. In some cases, chronic ingestion of
foods contaminated with certain types of fungi
and bacteria capable of converting nitrates to
N-nitroso compounds are suspected of playing
a causative role.

Franklin D. Loo, M.D.
Approximately 1 2,000 patients in the U.S. will
be diagnosed with esophageal cancer this year.
Esophageal cancer occurs in two histologic
distinct types; squamous cell carcinoma
accounted for over ninety percent of all
esophageal cancers. Today adenocarcinoma
has increased and now constitutes almost fifty
percent of all cases of esophageal cancer in the
United States. The cause for this relatively
sudden and dramatic change in histology is
unknown, but similar trends have been seen in
Europe.

Patients with celiac sprue, Plummer-Vinson
syndrome, lye ingestion strictures and tylosis all
have high risks of esophageal cancer.
B. Adenocarcinoma
The cause of adenocarcinoma is less well
understood. The only accepted risk factor for
adenocarcinoma of the esophagus is Barrett’s
Cigarette smoking and alcohol
esophagus.
consumption have not been linked to this form
of esophageal cancer. Barrett’s esophagus is
more frequently seen in patients with colon
polyps, implying a common primary genetic
mechanism. Chronic acid reflux, frequently

Epidemiology
The two histologic types of esophageal cancers
have strikingly different epidemiologies. In the
United States squamous cell cancer occurs six
times more commonly in African-American and
Asian populations. Conversely adenocarcinoma
of the esophagus occurs four times more com
monly in Caucasians.
15

asymptomatic in these patients, appears to
trigger the metaplastic change from squamous
mucosa to Barrett’s epithelium and subse
quently to adenocarcinoma.

Staging
Surgery remains the main curative therapy.
Therefore preoperative staging is crucial. CT
scans have been the primary staging modality
but endoscopic ultrasound appears to have a
great deal of promise with T stage accuracy
and N stage sensitivity of 70 90%.

Diagnosis
Both types of esophageal cancer are asympto
matic in the early stages. Only serendipity or
screening examinations for Barrett’s esophagus
permit early diagnosis. X-rays are especially
useful if sequential studies are needed.
Endoscopy is required to establish a histologic
diagnosis prior to surgery. Endoscopy is also
the only practical means for performing sur
veillance exams on patients with Barrett’s
esophagus.

-

Treatment
Surgery is usually undertaken with cure in
mind.
Occasionally palliation is attempted
surgically. Combined treatment protocols with
pre and post chemo and radiation therapy has
improved survival.
When cancer has extensively metastasized and
surgical palliation is not acceptable, several
endoscopic options are available.
These
include laser and photodynamic therapy or
stent placement.

Adenocarcinoma of the esophagus is thought
to be preceded by the development of dys
plastic lesions in the affected segment. The
progression of dysplasia to cancer has been
compared to the well described and confirmed
colon polyp colon cancer sequence. Unfor
tunately with dysplasia in the esophagus there
is greater controversy regarding the histologic
criteria required for the diagnosis. There is
frequent disagreement between different
pathologists reviewing the same sections. To
complicate the issue dysplastic changes can
frequently be reversed by aggressive anti-ulcer
therapy; although some experts suspect in
those cases there was some misreading of the
original specimens.

The former two approaches may occasionally
be considered non-operative approaches for
cure but these techniques and their efficacy in
bringing about cures of very early lesions
remains controversial and to be validated.

-

Nd:YAG Laser therapy has been advocated for
tumor ablation of bulky tumors with or without
stricture that cause dysphagia. Advantages of
laser therapy include relative ease of the
procedure and the lack of a prosthetic requirement. Disadvantages include the need for
repeated endoscopic procedures, a risk of
perforation, bleeding and no effect on tumor
pain. Dysphagia persists to some degree but
usually improves with treatments.

Annual examinations have been recommended
for Barrett’s esophagus.
Several recent
investigators are recommending a surveillance
schedule on alternate years, based on risk
benefit statistics. When low grade dysplasia is
found surveillance exams are recommended at
eight weeks and again in six months. If high
grade dysplasia is found and confirmed, an
esophagectomy is recommended. Given this
fairly drastic recommendation, confirmation of
high grade dysplasia by several pathologists is,
of course, required. Attempts at enhancing the
diagnostic yield with vital stains has proved
disappointing. Proposed bio-markers currently
being evaluated include mucous abnormalities,
flow cytometry and tumor suppression gene
P53 expression.

In Barrett’s esophagus laser therapy has been
touted as a means of reversing the metaplastic
change i.e., re-epithelializing the Barrett’s
esophagus with squamous mucosa. Recently
there’s been a report of adenocarcinoma devel
oping in the esophageal segment of Barrett’s
that had been re-epithelialized with squamous
tissue. If this is true, the malignant potential is
not lost after laser induced treatment. Because
of this concern there has been a decrease in
the enthusiasm of treating Barrett’s esophagus
with laser.
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silastic) and expanding wire mesh stents have
been used for palliation. The rigid stents offer
the advantage of occluding fistulas, for exampIe tracheoesophageal-esophageal fistulas, and
preventing tumor growth into the lumen. Wire
mesh stents are better tolerated by the patient
but do permit tumor ingrowth. Lesions in the
distal or middle third of the esophagus are best
suited for plastic stenting. The mesh stent is
more versatile and can be placed more easily in
proximal and very distal lesions.

Photodynamic therapy (PDT) is a different type
of laser treatment from Nd:YAG thermal abla
tion for esophageal cancer. PDT consists of
administration of a chemical sensitizer that
accumulates in the tumor with greater concen
tration than in normal tissue. The chemical is
then activated by the application of light to the
area of the tumor with a low power laser.
Tumor necrosis results from a photochemical
rather than a thermal affect. PDT is compar
able to laser in terms of palliation of dysphagia
but objective tumor response appears to be
greater for PDT. On average PDT requires
However,
fewer endoscopies than laser.
patients are photosensitized and must avoid
Perforation and
sunlight for two months.
bleeding are less common for PDT in the early
studies but side effects of nausea, fever,
pleural effusions and chest pain are much more
common. PDT appears to be equally effective
for squamous and adenocarcinoma.

In summary, carcinoma of the esophagus is a
disease in evolution. Of the estimated 1 2,000
patients who will be diagnosed in the U.S. this
year only 7% will survive five years. Out of
the 100 patients who actually go to visit a
doctor, 58 will be explored, 39 resected, 26
leave the hospital with tumor excised ( 29%
operative mortality), 1 8 survive for one year, 9
for two years and 4 for five years. The bright
spot is that adenocarcinoma, which is increas
10% per year
ing at a rate of between 4
(replacing squamous cell carcinoma) is more
amenable to early detection and prevention.
Interruption of the acid reflux-Barrett’s esoph
agus-adenocarci noma sequence, along with
new treatment modalities such as PDT,
hopefully will have an impact on the dismal
survival statistics of this disease.

One intriguing application for PDT is for
patients with Barrett’s esophagus who have
high grade dysplasia. This subset of patients is
being evaluated with PDT therapy for the
dysplastic lesions The anecdotal experience
has been good but prospective randomized
studies are required.

-

.

Finally both rigid (plastic polyethylene and
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CURRENT ISSUES IN ESOPHA GEAL CANCER SURGERY
By John F. Just, MD.
is better than CT scanning in assessing the
depth of the tumor infiltration and regional
adenopathy.
Neoadjuvant therapy recently has been added
to reduce the bulk of the tumor and attempt to
eradicate tumor in lymph nodes and thereby
downstage the disease. It may reduce dissem
ination during surgery because it is delivered
prior to the surgical disruption of the blood
supply to the tumor. Preoperative radiation
therapy as well can reduce tumor bulk, render
some specimen sterile and should not increase
postoperative morbidity and mortality. Pre
operative chemo-radiation therapy has resulted
in 40% five year survival for patients with
documented pathological remission.
The operative procedures for resectable
esophageal cancers have substantially changed
recently.
The initial operative procedure
described by Ira Lewis in England in the midforties was a laparotomy and creation of a
gastric tube followed by a right thoracotomy
and resection of the esophagus with subse
quent pull up of the gastric tube into the right
chest. The current blunt esophagectomy cham
pioned by Dr. Oringer from the University of
Michigan has become quite an acceptable
alternative to avoid some of the previous
complications associated with the placing of
anastomosis in the right chest. While not being
able to resect in the classical en block manner
the long-term survival rates are as favorable
with the transhiatal approach.

John F. Just, M.D.
Unlike Iran, China and Russia where there are
500 cases per 1 00,000 people, in the United
States the incidence is 5 cases per 100,000
people. Age, alcohol, dietary and nutritional
factors, race and smoking all are implicated in
the epidemiology of esophageal cancer. Squa
mous cell cancer is the most frequent cell type,
but there has been an increase in adeno
carcinoma of the esophagus in the last fifteen
years, specifically in the arisal of cancer from
Barrett’s mucosa, where the risk of developing
cancer is 50 to 100 times that of normal
esophageal mucosa. Often dysplasia precedes
malignancy. Whereas low grade dysplasia may
remain stable or regress, high grade dysplasia
is equivalent to carcinoma in situ. Endoscopic
surveillance is necessary to detect and treat the
cancer early and to improve survival.

Since the esophagectomy is the most dangerous of the elective thoracic procedures one
tries to minimize the complication rate. In the
transhiatal approach the patient is operated
upon in the supine position, the abdomen is
open, the duodenum freed up using a Kocher
maneuver and a pyloroplasty performed if there
is no evidence of intra-abdominal spread of the
disease. A gastric tube is formed by leaving
the right gastric and the right gastroepiploic
vessels intact while ligating the remaining
vascular arcades (see figure 1).

Barium swallow and endoscopy are compli
mentary in eary detection. CT scanning is
useful in tumor staging and in detecting distant
metastasis, and as a surveillance tool postoperatively. Endosonography provides detailed
images of the esophageal wall and adjacent
structures for staging esophageal cancer, and
18

The left neck is opened and the esophagus is
freed up from the surrounding tissues with
careful attention to avoid injury to the recurrent
laryngeal nerve. The thoracic esophagus is
freed up in a blunt manner as well from the
mediastinum through the neck incision. The
esophagus is removed in a retrograde fashion
after being divided in the neck (see figure 4).

)‘v:L
figure 1
The stomach is then transected using surgical
stapling instruments so that a gastric tube is
formed with the apex of the fundus of the
stomach being the ultimate site of the anasto
mosis between the cervical esophagus and the
gastric tube (see figure 2).

figure 4
The gastric tube is brought through the native
bed of the esophagus to the neck where the
hence, any
anastomosis is performed;
subsequent leak can be managed by drainage
through the neck incision ( see figures 5 and 6).

figure 2
The dissection is then carried out through the
hiatus which is opened enough to let the dis
section proceed and bluntly the esophagus is
removed from the mediastinum ligating vessels
as necessary (seefigure 3).

figure 5
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figure 3
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figure 6

Alimentation is maintained through a feeding
jejunostomy and after the fifth or sixth day,
assuming there are no further complications
and there is no leak at the anastomosis,
feedings are begun.
The jejunostomy will
remain in place until the patient is eating a
regular diet and is removed as an outpatient.
The patient may lose ten to fifteen pounds over
the next four to six months while eating four
smaller meals a day with nothing to eat or drink
after the evening meal.
The long term results of the esophagectomy
can accomplish the primary mission which is to
restore the patients ability to eat and drink for
the remainder of his lifetime. Survival rates
have been increasing in the last several years
and the current status of neoadjuvant therapy
to downstage tumor in order to increase
survival has yet to be defined.
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RADIA TION THERAPY FOR CARCINOMA OF THE ESOPHAGUS
By Kevin J. Murray, IfrLD.
and lymph node involvement just prior to
This can
becoming widely disseminated.
happen well before clinical symptoms are
manifested since there is little to contain the
spread of cancer and prevent extension into
surrounding adjacent structures. Even following aggressive surgery and radiation therapy,
the majority of the patients failed locally and a
substantial number do develop distant disease.
The majority of patients present with symp
toms of approximately 3 4 month duration.
Dysphagia (difficulty swallowing) and weight
loss are seen in over 90% of patients. Odyno
phagia is also present in approximately 50%.
Because these tumors can locally invade into
adjacent structures such as the lung and
bronchial tree, the patients can present with
hemoptysis and persistent cough.
-

‘

Following biopsy to establish the diagnosis, all
patients should be considered for possible
surgical excision of this tumor. This generally
involves the subtotal or total esophagectomy.
If the patient is not felt to be a candidate for
surgical removal either due to underlying
medical conditions or due to the extensive
nature of the tumor, the next course of therapy
is to consider combined chemotherapy and
external beam radiation. Large numbers of
studies have been published looking at combin
ations of chemotherapy, mainly 5-FU but also
Bleomycin, Vincristine and Methotrexate
combined with radiation therapy prior to
consideration of surgery. Complete response
rates have been reported anywhere from 30
90% using combination therapy. Substantial
improvement in overall survival can be found in
those patients who do have an excellent
response to their initial management.

Kevin J. Murray, M.D.

Carcinoma of the esophagus represents roughly
1 % of all cancer in the United States. In 1990,
there are an estimated 1 0,600 new cases of
which approximately 7500 were men and 3100
were women. The majority of patients present
in the middle years between the ages of 55 and
65. This tumor is found world wide though
some areas such as in Iran, the Soviet Union
and in China, there can be markedly high mcidences of esophageal cancer which is felt to be
related to dietary changes.

-

In the United States, the major risk factors for
the development of esophageal malignancies
are alcohol and tobacco use with approximately
80 90% of all cases. Certain food products
especially dietary intake of nitrates (especially
found in cured meats and smoked fish) are also
associated with the development of this tumor.

One of the largest studies to compare the use
of external beam irradiation alone versus ex
ternal beam irradiation combined with chemo
therapy was a cooperative group study between the Radiation Oncology Group, Southwestern Oncology Group, and the North Central
Cancer Therapy Group. This study randomized

-

This tumor has a tendency to grow quite
insidiously and develops extensive local growth
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1 20 patients between external beam irradiation
alone to 6400 cGy versus 5000 cGy plus
chemotherapy consisting of 5-EU and Cisplatin.
All patients were able to complete their
therapy. The 2 year survival for the radiation
therapy alone group was 10% while it was
42% for the combined modality therapy. This
result was highly statistically significant. It was
noted that the patients receiving combined
modality therapy tended to have fewer local
recurrences as well as recurrences in regional or
distant sites.
It was overall felt that this
combined therapy was well tolerated with
acceptable levels of toxicity.

generally recommended for the treatment of
this disease. Modifications of this approach are
made depending on bulk of disease as well as
patients overall status.
An additional radiation therapy technique
involves the use of placement of a central
catheter into the esophagus using a naso
gastric approach. Inside of this catheter, a
radioactive isotope such as a Iridium-192 can
be placed. This radioactive source emits low
energy x-rays at a relatively high dose rate and
can deliver substantial doses of irradiation to
the surrounding esophageal tissues with little
delivery of radiation to the surrounding normal
structures. While this technique has a great
deal of utility in the treatment of extensive local
lesions of the esophagus, it is difficult to treat
the entire esophageal tumor due to its propen
sity to spread substantially beyond its visible
borders. This makes it then difficult to determine the exact placement of the radioactive
sources.

When using radiation therapy techniques in the
treatment of esophageal tumors, the majority of
patients will receive a course of externally
directed irradiation. The key in the treatment
of these patients is to make sure that the
volume treatment adequately encompassed the
tumor as well as a margin of normal tissue.
Generally a margin of 5
6 cm. above and
below the tumor is recommended due to the
well known capability of this tumor to extend
far beyond its visible borders. Additionally,
appropriate care must be taken to minimize the
dose to the multiple surrounding normal
structures ‘which include the bronchial tree,
lungs, heart, aorta and spinal cord. Generally
patients are treated while lying on their back
using a series of treatment directions from the
front and back or from the front in both pos
tenor obliques. CT scans in conjunction with
computerized treatment planning are used to
help maximize the dose to the target volume
while minimizing the dose to the surrounding
normal tissues. A dose of approximately 50
60 Gy (5000 6000 rads) in 5 6 weeks is
-

When the radiation is used to help relieve the
symptoms that patients can experience
(especially pain on swallowing or a sensation
that food is unable to completely pass through
the esophagus) patients can be effectively
palliated in the upwards of 80% of the cases.
Generally somewhat lower total doses on the
order of 30 45 Gy (3000 4500 rads) in a
treatment duration of 2 3 weeks are utilized.
-

While advances have been made in the treatment of this difficult disease especially in the
areas of combined chemotherapy, radiation and
surgery, the overall outlook for these patients
needs further work and study.

-

-

-

-

-
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CINOMA
CURRENT ROLE OF CHEMOTHERAPY FOR ESOPHA GEAL CAR
.
By Robert F. Taylor, M.D
suggest that metastatic disease and lymphatic
spread represent a significant risk to such
patients and are not addressed adequately by
surgery alone. A recent autopsy study from
Hong Kong demonstrates systemic disease
even at or shortly after initial presentation. The
majority of patients in that series were found to
have evidence of distant metastatic disease,
even if it did not contribute substantially to
their mortality. Clearly, the need to address
dissemination must involve the use of systemic
therapies, and chemotherapy therefore has
been considered.
Preoperative Neoadjuvant Chemotherapy
There are several possible techniques for
utilizing chemotherapy in the treatment of
esophageal carcinoma. One such approach is
to use drugs in a so-called “neoadjuvant”
In this modality, patients with
setting.
advanced esophageal carcinomas received
chemotherapy prior to definitive surgery or
a
radiation. This approach has been used in
oid
epiderm
both
with
s
variety of trials in patient
and adenocarcinoma. In an early trial reported
by Coonley, 34 patients with an epidermoid
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Robert F. Taylor, M.D.
Carcinoma of the esophagus presents a
persistent therapeutic challenge to oncologists
and surgeons. Approximately 1 1 ,000 new
cases will be diagnosed in the country, and the
vast majority of these will die from their
disease. The cancer itself represents 1 .9% of
all cancer deaths in the United States, and a
particularly disturbing trend reveals that
adenocarcinoma of the esophagus now
represents a larger percentage of esophageal
cancers, whereas squamous cell carcinoma,
which is more favorable in Its prognosis and its
response to treatment, used to represent a
much higher percentage. Approximately half of
the newly diagnosed cases now have adeno
carcinoma and half epidermoid carcinomas.

.

Surgical treatment for resectable esophageal
cancer has resulted in a five year survival of
between 5 and 20%. Surgical mortalities, in
some series, can run as high as 20% however,
negating any potential benefit of that treatFurthermore, patterns of recurrence
ment.
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tration of preoperative chemotherapy is safe
and without side effects; however, the overall
survival has still been disappointing with
median survivals ranging between 10 and 26
months, which is not a substantial improvement over historical surgical controls.

performed and are ongoing, to demonstrate a
favorable response in this regard. Most of
these have addressed the contribution of
additional chemotherapy agents to preoperative
chemo-radiotherapy, includi ng etoposide,
leucovorin and combinations of those two
drugs. To date, comparable rates of resectability, pathologic complete responses and
survival have been observed in these trials,
when compared to the prior studies.

Neoadjuvant Chemotherapy with Radiation
Attempting to intensify the effects of pre
operative chemotherapy, in patients with
esophageal carcinoma, has led to the use of
combined modality therapy in this setting. It is
known that both cisplatinum and 5 EU are
radiation sensitizers and, as such, it is not
surprising that such patients would benefit
from a combined modality (radiation and
chemotherapy) in this setting. Several such
studies have been published.
An Eastern
Cooperative Oncology Group phase Ill trial,
utilizing chemotherapy and radiation versus
radiation alone, showed no difference in
survival. Concurrent radiation and infusional 5
EU has been felt to be helpful, but for the most
part has not been successful in prolonging life
in the absence of surgery.

Palliative Therapy
Chemotherapy and radiation therapy, without
surgery, have been used in a palliative mode for
patients deemed either unable to tolerate
esophagectomy or those who refuse the procedure. Again, the group from Wayne State
studied this approach utilizing 5 EU and
cisplatinum followed by radiation therapy.
Median survival in this series was 22 months,
although approximately half continued to have
persistent local regional tumor after such
treatment.
Similar studies have confirmed
similar findings in those patients treated with
combined modality approach.

Chemo-radiotherapy has also been used in
conjunction with surgery, in a trimodality
approach. Several trials have been published in
this regard, the earliest one being from Wayne
State which utilized, a combination of 5 EU and
mitomycin-C and 5 EU and cisplatinum adminis
tered for two cycles with radiation therapy
being given concurrently, with the first cycle of
chemotherapy followed by an esophagectomy.
Pathologic complete responses to chemo-radio
therapy were seen in between 20 and 24% of
the patients; however, the median survival
remained relatively short at 18 months. Even
amongst patients with complete clinical
responses, all had eventually succumbed to
metastatic disease without evidence of local
tumor recurrence.

The role of chemo-radiotherapy remains somewhat uncertain. Major response rates have
been reported in between 40 and 80%, and up
to 24% pathologic responses have been
achieved.
Despite this however, median
survivals remain quite disappointing at between
1 1 and 29 months. There is currently no consensus on the role of combined chemo-radio
therapy in such patients, except inasmuch as it
does appear to provide palliative treatment for
many patients with this disease, and this
approach remains somewhat investigational. In
a nonsurgical setting, recent evidence would
strongly suggest that concurrent chemotherapy
and radiation therapy is superior to radiation
therapy alone, in the control of locally
advanced disease. The question of whether or
not an esophagectomy is necessary awaits the
results of a randomized trial.

A subsequent study, done by the Southwest
Oncology Group and the Radiation Therapy
Oncology Group, evaluated 106 patients
treated in a similar fashion.
Pathologic
complete responses were seen in 17%, but
median survival for all patients was only 1 2
months. This study also failed to demonstrate
a substantial improvement for the combined
modality arm. Multiple other studies have been

Future Directions
Clearly additional chemotherapy agents are
essential to improvement in overall survival of
this disease. While the addition of cisplatinum
to the 5 EU combination has increased re
sponses. Newer antitumor agents are needed.
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pressor genes in the mechanism of tumori
genesis. Similarly, the tumor suppressor gene
P53 has been studied, and P53 mutations have
been demonstrated in a variety of esophageal
both adenocarcinoma and
carci nomas,
squamous cell carcinoma, and in Barrett’s
epithelium. The use of agents which affect the
expression of an epidermal growth factor
receptor, and the P53 gene, may be important
in the development of esophageal carcinomas.
Clearly, such agents are several years from
clinical trials that may ultimately produce the
needed breakthrough which will allow eradica
tion of this very aggressive and highly
malignant disease.

Leucovorin as a biomodulator of 5 EU may have
efficacy in this disease, and this combination
has been shown to have effectiveness against
epidermoid carcinomas. Similarly, using infu
sional 5 FU and leucovorin in combination with
cisplatinum may provide a potential advantage
as well.
Additionally Interferon Alfa 2a, as a biomod
ulator for 5 EU, has been suggested as a means
to improve response without increasing toxicity
excessively, although clearly hematologic
toxicity may become important in such a
combination. The ongoing studies indicate a
potential role for oncogenes and tumor sup-
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CANCER OF THE ESOPHAGUS
PA TIENT CARE EVALUA TION STUDIES

Annual Studies
This study includes all carcinomas. Excluded
from the study are sarcomas, melanomas and
Primary
plasmacytomas of the esophagus.
carcinomas of the esophagogastric junction are
not included in the study.

Annually the Cancer Committee conducts at
least one long-term and short-term patient care
In 1 995 the committee
evaluation study.
chose to participate in the esophageal cancer
study, which was the current study being
conducted by the American College of
Surgeons (ACOS), Commission on Cancer
(CCC). The long-term study includes the cases
accessioned in 1 989 and 1 990. The shortterm study represents cases accessioned in
1994.

ESOPHAGEAL CANCER STUDIES
SYMPTOMS PRESENT AT DIAGNOSIS

Electronic Submission

PERCENT

This study is different from past evaluations in
that the short-term study is submitted electronically via the National Cancer Data Base (NCDB)
Call for Data to the ACOS. Over time, outcome
data from this short-term esophageal cancer
study will be collected through the NCDB Call
for Data. Electronic data submission allows the
NCDB staff to link current follow-up data to
previously submitted data.
Purpose of the Studies
,

This study of esophageal cancer is designed to
document the current methods of diagnosis,
treatment, and staging, and survival. This
information is reviewed by the Cancer Com
mittee to identify opportunities for improving
patient care and analyze the causes of study
variations.
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Case Selection Criteria
Presenting Symptoms

Patients must have a histologically confirmed
primary cancer of the esophagus that was
either diagnosed and/or initially treated at this
hospital. Patients that have been diagnosed
with histologically proven metastasis, having
clincal evidence of a primary tumor are to be
included.

Esophageal cancer rarely causes symptoms
until the esophagus has been encircled
completely by cancer. The two main symptoms
present at time of diagnosis were dysphagia
and weight loss. The patients main reason for
seeking medical attention was difficulty eating.
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Chronic cough and hoarseness were present
less often.

ESOPHAGEAL CANCER CASES
1978

-

1995

ESOPHAGEAL CANCER STUDIES
TOBACCO AND ALCOHOL USE HISTORY
—

,

]-CARCINOMANOS
OTHER

1-

EXSMOKER

CURRENT SMOKER
67%

ERATINIZING SQ. CELL

ADENOCARCINOMA NOS

TOBACCO USE

-

TOBACCO USE

1 989

-

1994
F SQUAMOUS CELL CA

FORMER USE

6 DRINKS
33%
-

3 DRINKS
33%

2DRINKS—
17%
3 C

NONE
17% FORMER USE
17%

DAILY ALCOHOL USE

-

1989

DAILY ALCOHOL USE

HISTOLOGY DISTRIBUTION
-

1994

Risk Factors

ESOPHAGEAL CANCER 1978
PATIENT AGE AND SEX RATIO

Cancer of the esophagus accounts for between
one and two percent of all cancers in the
United States and occurs three times as often
in men as in women. These trends are also
present at West Allis Memorial Hospital
fWAMH). Individuals in the sixth and seventh
decades are affected most often at WAMH.
This is a decade younger than the national
average. Smoking along with the consumption
of alcohol have been linked to esophageal
cancer. Case histories have shown that the
majority of persons who develop this type of
cancer have a history of heavy smoking, heavy
drinking or heavy smoking and drinking
combined.

NUMBER OF PATIENTS

Pathology

Squamous cell carcinoma including keratinizing
squamous cell carcinoma account for over 58%
of the esophageal cancers. Adenocarcinoma is
is in second place totaling 30% of the cases at
WAMH.

40-49

50-59

60-69

70-79

AGE RANGE
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80-89

-

1 995

tESOPHAGEAL CANCER CASES

L

1g78-1995

CHEMOTX—
SURG/RAD
SURGERY
SURG/CHEM/RAD—___________
—CHEM OTX/RAD

FIRST COURSE OF THERAPY

TREATMENT COMBINATIONS

Treatment
demiology and End Results (SEER) data WAMH
had 10% more patients staged with regional
stage (direct extension and/or regional lymph
nodes) and the same percentage of distant
stage. The unstageable category, for the most
part, includes patients who either refused
staging workup and/or were in terminal
condition at the time of diagnosis. The WAMH
five year survival table reflects this as none of
the unstageable cases survived five years.
WAMH survival rates compare very favorably
with SEER data. The overall five year survival
rate for all stages reflects that WAMH patients
have a five percent higher survival rate. The
five year survival rate differences for local
stage are higher and statistically significant for
WAMH when compared to SEER data.

Radiation therapy was the most often used
modality at WAMH for the treatment of
esophageal cancer. Radiation was used either
by itself or in combination with other modalities
in 46% of the cases. Chemotherapy was used
either by itself or in combination with other
modalities for 38% of the esophageal cancers.
Surgery was used in only 17% of the cases.
Fifteen percent of the cases received no
treatment.
Stage at Diagnosis
In the majority of the cases the treatment was
palliative only because of advanced disease or
because of local extension to vital organs at the
time of diagnosis. When comparing the stage
at diagnosis at WAMH with Surveillance, Epi
29
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ESOPHAGEAL CANCER
STAGE AT DIAGNOSIS COMPARISONS

STAGE AT DIAGNOSIS
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2
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271_
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27

17
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PERCENTAGE OF CASES
\

‘

ESOPHAGEAL CANCER
FIVE YEAR SURVIVAL RATES+

ALL
STAGES

LOCAL

REGIONAL

DISTANT

UNSTAGED

WAMH**

11%

40%

4%

4%

0%

NCI
SEER*

6%

13%

4%

1%

6%

*NCI

SEER

National Cancer Institute Surveillance Epidemiology & End Results Program
Accession years in survival calculations 1 974 1 986
-

-

**

WAMH

+ Survival Rates

West Allis Memorial Hospital
Accession years in survival calculations

1 978

-

1 995

Survival rates are calculated by Actuarial (Life Table) Method.
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GLOSSARY
Accessioned

Entered into the Cancer Registry data base

ACoS, COC

American College of Surgeons, Commission on Cancer. In 1 932 the American
Cancer Society urged the American College of Surgeons to take the lead in
setting guidelines for cancer care. Approval of hospital-based cancer programs
by the Commission on Cancer has been the foundation for improving the quality
of patients with cancer. Certification of a cancer program by ACoS, COC
indicates that standards for optimal cancer patient care are in place.

ACS

American Cancer Society

AJCC

American Joint Committee on Cancer organized for uniform cancer staging and
end results reporting

Analytic Cases

Cases which are first diagnosed and/or received all or part of their first course
of therapy at West Allis Memorial

Cancer Stage

The extent of cancer spread determined at the time of initial workup

First Course
of Therapy

The initial tumor-directed treatments, usually initiated within four months
following diagnosis

Non-Analytic Cases

-

Cases which were diagnosed elsewhere and received first course of therapy
elsewhere or were diagnosed and treated here prior to the cancer registry start
date of January 1 1 978. These cases are seen for subsequent treatment for
either persistent disease or recurrent disease. Also includes those cases
diagnosed at autopsy
,

SEER Program

SEER
Summary
Staging

Cancer Surveillance, Epidemiology, and End Results reporting program of the
National Cancer Institute of the National Institutes of Health
In situ

-

Localized
Regional

Distant

-

-

-

Unknown

TNM Staging

-

Neoplasm which fulfills all microscopic criteria for malignancy
except invasion
Neoplasm which appears entirely confined to the organ of origin
Neoplasm which has spread by direct extension to immediately
adjacent organs or tissues and/or has spread to regional lymph
nodes and no further
Neoplasm which has spread beyond immediate adjacent organs
and/or has metastasized to distant lymph nodes or is systemic
in origin
Stage cannot be determined from the medical record or a medical
authority

AJCC classification to determine the extent of cancer at the time of diagnostic
workup for the first course of therapy
T Extent/size of primary tumor
N Extent of lymph node involvement
M Extent of distant metastasis
-

-

-

Survival

Survival statistics were calculated using the actuarial method for observed
survival
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